Tracheomalacia
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Catapult TherapeuticsNetherlands - Lelystad
1 program1
Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cellsPhase 11 trial
Active Trials
VideregenUK - Leeds
1 program1
Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cellsPhase 1
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Catapult TherapeuticsCadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
Clinical Trials (1)
Total enrollment: 4 patients across 1 trials
NCT02949414Catapult TherapeuticsCadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells
Start: Sep 2016Est. completion: Sep 20244 patients
Phase 1Suspended
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.